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Abstract
Background: Nowadays, there are two vaccination strategies in Colombia to prevent pneumococcal diseases in
people over 50 years. Our aim is to estimate cost-effectiveness of pneumococcal conjugate vaccine 13-valent (PCV13)
versus pneumococcal polysaccharide vaccine 23-valent (PPSV23) to prevent pneumococcal diseases and their related
mortality in people over 50 years old in Colombia.
Methods: A Markov model was developed with national data, including pneumococcal serotypes distribution in
Colombia between 2005 and 2010. Vaccination of a cohort was simulated and a five year time horizon was assumed.
Analysis was done from a perspective of a third party payer. Direct costs were provided by a national insurance
company; sensitive univariate and probabilistic analysis were done for epidemiological and clinical effectiveness
parameters and costs.
Results: PCV13 avoids 3 560 deaths by pneumococcal infections versus PPSV23 and 4 255 deaths versus no vaccine.
PCV13 prevents 79 633 cases by all-cause pneumonia versus PPSV23 and 81 468 cases versus no vaccine. Total costs
(healthcare and vaccines costs) with PCV13 would be U.S. $ 97,587,113 cheaper than PPSV23 and it would save U.S. $
145,196,578 versus no vaccine.
Conclusion: PCV13 would be a cost-saving strategy in the context of a mass vaccination program in Colombia to
people over 50 years old because it would reduce burden of disease and specific mortality by pneumococcal diseases,
besides, it saves money versus PPSV23.
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Background
Streptococcus pneumoniae (pneumococcus) is a frequent
cause of serious infectious diseases in children and adults.
Pneumococcal infections may be invasive such as sepsis
and meningitis [Invasive Pneumococcal Disease (IPD)], or
non-invasive, such as pneumonia, the most common form
of serious pneumococcal disease in adults [1]. According
to the World Health Organization (WHO), in 2000 there
were about 14.5 million cases of pneumococcal disease
(invasive and noninvasive) [2].
Pneumococcal pneumonia is the most common bac-
terial cause of community acquired pneumonia (CAP)
in adults [3]. Mortality rates for pneumococcal CAP are
between 10% and 30% in adults and have remained
constant over the past four decades [4-8].
Increased bacterial resistance [9], an increase in the
prevalence of immunocompromised people, especially
by HIV, immunosuppressive therapy in oncology, and
transplantation medicine; as well, the increase in life
expectancy that is accompanied by immune senescence
processes likely contribute to sustained morbidity and
mortality impact of this disease [10,11].
Given the burden of disease by pneumococcal diseases
in worldwide, a prevention strategy with vaccination may
be the most cost-effective approach to health systems.
This is not a new topic, there are randomized clinical trials
(RCTs) from 1940s [12,13], but it was just until 1977 that
began the widespread use of this technology, when
pneumococcal polysaccharide 14-valent vaccine (PPSV14)
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was authorized and later, in 1983, PPSV23 was launched.
The latter is a vaccine made with 23 different capsular
polysaccharide serotypes and has been indicated to
prevent pneumococcal disease in children over two years
old with risk factors and adults over 50 years old. Inter-
national clinical guidelines generally recommend its use in
adults over 65 years old, and for people under 65 years
old, who have chronic comorbidities that put them at
higher risk of disease [14].
In 2000, a pneumococcal vaccine with a different tech-
nology was launched, which conjugates pneumococcal
serotypes with a diphtheria protein (CRM197). This one
was the pneumococcal conjugate vaccine 7-valent (PCV7)
that demonstrated its effectiveness [15-17] to prevent IPD,
pneumonia and acute otitis media (AOM) caused by
vaccine serotypes in children aged between 2 months and
9 years old. It has also been studied in adults, including
patients with HIV [18]. Later, in 2006, a WHO expert
group established that future pneumococcal conjugate
vaccines may be evaluated on the basis of immunogen-
icity studies, such that efficacy studies with disease
outcomes would not be necessary for regulatory approval.
This statement was based on the PCV7 and PCV9 RCTs,
that found an association between an antibody concen-
tration > 0.35 mcg/ml of the serotypes contained in
these vaccines and prevention of IPD by the respective
serotype [19].
In 2010, a 13-valent pneumococcal conjugate vaccine
(PCV13) was approved for prevention of IPD, pneumonia
and AOM caused by serotypes included in the vaccine in
children between 2 months and 5 years old. Later, in 2011,
PCV13 was approved to use in people over 50 years to
prevent pneumococcal diseases (IPD and pneumonia)
caused by serotypes 1 3, 4, 5, 6A, 6B, 7 F, 9 V, 14, 18C,
19A, 19 F and 23 F.
Given that there are two technologies for prevention
of pneumococcal diseases in people over 50 years old,
the 23-valent polysaccharide vaccine and the 13-valent
conjugate vaccine, the aim of this study was to estimate
incremental cost-effectiveness ratio (ICER) of PCV13
versus PPSV23 and versus no vaccine in people over
50 years old in Colombia.
Methods
Model
A cost-effectiveness analysis was performed using a Markov
model with a first-order microsimulation to determine the
risk of developing IPD and pneumonia in people over
50 years; the original model was developed by PAI (Policy
Analysis Inc.) to Pfizer. The model simulates cohorts of
individuals which represent the age and risk profile of the
populations. Each individual’s risk was adjusted based on
age and risk profile of individuals according to their medical
history, such as chronic diseases or immunocompromised
illnesses. No previous vaccination with PPSV23 was as-
sumed. The model assumed that at the beginning, indi-
viduals would be vaccinated with PCV13 or PPSV23 or
would not be vaccinated. Over the course of the simula-
tions, individuals were at risk for four clinical outcomes:
sepsis, meningitis, inpatient pneumonia and outpatient
pneumonia. Mortality rates from IPD and pneumonia were
considered to calculate deaths avoided. Risk reduction
associated with the vaccines relied on the clinical presen-
tation of diseases: IPD, inpatient pneumonia or outpatient
pneumonia; as well as the vaccine, time since vaccination,
age at time of diseases, and risk profile [20] (Figure 1) Fur-
ther methodologic details can be referenced from applica-
tion of the model to the US setting [20].
Costs of medical treatments were calculated based on
the site of healthcare (inpatient or outpatient), age of
patients, and their risk profile. To determine epidemio-
logic distribution of S. pneumoniae serotypes, we used
the data of Regional Vaccine System (SIREVA II, by their
acronym in Spanish), which reports serotypes of all iso-
lates made in Colombia by IPD. For this purpose, we took
the distribution of S. pneumoniae serotypes found in
Colombia between 2005 and 2010 in people older than
50 years [21]. The model was calculated using a discount
rate of 3% for both costs and effects, according to WHO
recommendations [22].
Analysis was done from the perspective of a third-party
payer in Colombia. Three alternatives were considered: no
vaccination, vaccination with PCV13 or vaccination with
PPSV23. The model horizon was five years and we as-
sumed vaccination coverage of 70%. An incremental
cost-effectiveness analysis was made among these three
strategies in terms of avoiding cases and deaths for each
disease and life-years gained (LYG).
The data used in this study are referenced in each item
and are publically available in medical databases and official
reports of Colombia, except hospitalization costs, which
were provided by SURA, a national health insurance.
Demographic and epidemiological parameters
The vaccinated cohort was calculated based on official
data from a projection of population over 50 years in
Colombia in 2012 (Table 1) [23]. The proportion of
people in each age group with low, medium, or high risk
for pneumococcal diseases or related complications was
based on a study of pneumococcal disease burden in older
adults in the United States (Table 2) [24]. The risk groups
were classified as follows [25]:
 Low risk: immunocompetent people without
chronic diseases.
 Medium risk: immunocompetent people with
chronic diseases, such as cardiovascular, hepatic,
lung illnesses or diabetes.
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 High risk: immunocompromised people as a result
of splenic dysfunction, malignancies, HIV, organ
transplant or chronic renal failure.
The model assumed that high-risk people who were
vaccinated with PPSV23 will be revaccinated five years
later [26].
We calculated the likelihood of falling ill with IPD,
inpatient pneumonia or outpatient pneumonia based
on two age groups of 50–64 years, and > 65 years. No
literature that would identify the specific risk for additional
age groups was found (Table 1) [27-30]. Mortality by IPD
and pneumonia was calculated according to official data
of general mortality by age groups in Colombia [31] and it
was adjusted based on Koivula et al. [32].
Pneumococcal serotype distribution in adults older than
60 years between 2005 and 2010 in Colombia was based
on reports of SIREVA II. Thus, proportion of S. pneumo-
niae serotypes circulating in Colombia covered by each
vaccine was calculated, as well: PCV13 covers 64.6% and
PPSV23 covers 76.9% [21].
Vaccine effectiveness
IPD
Parameters of effectiveness of initial vaccination with
PPSV23 in immunocompetent adults over 50 years
and immunocompromised adults over 65 years were
adapted from the approach by Smith et al., and it was
adjusted for age, risk group, and time since vaccination
[33]. As these data were taken from a panel of experts
through Delphi methodology, sensitivity analysis and
probabilistiva analysis were done [34], and these have been
consistent with former results in the United Kingdom
[35]. Effectiveness of initial vaccination with PPSV23 in
immunocompromised adults between 50 and 64 years
old in the year after vaccination was based on data from
Shapiro et al. [34]. In the same way, we assumed a rate
of decline in protection after vaccination [10]. It was
assumed that the effectiveness of revaccination with
PPSV23 was 75% of initial value (Table 3).
Effectiveness of PCV13 for people over 50 years in the
groups of low and moderate risk in the year after vaccin-
ation, was adapted from the effectiveness of PCV7 for
children [15,35,36], assuming similar effectiveness against
the six pneumococcal serotypes not included in PCV7. It
was assumed a conjugate vaccine would have similar ef-
fectiveness as in children, but that this effectiveness would
decline with increasing age after 50 due to immune-
senescence. The decline in PCV13 effectiveness with
age in people over 50 years was assumed as 50% of the
corresponding rate of decline for PPSV23. Further for
people in high-risk group, it was assumed PCV13 would
have 78% of the corresponding age-specific effectiveness
of adults with low and moderate risk [37]. It was assumed
that effectiveness of both vaccines was constant across
each of the serotypes contained in each vaccine, ac-
cording to WHO recommendation of non-inferiority
in the proportion of vaccine serotypes with antibody
levels > 0.35 mcg/ml [38,39] (Table 3).
All cause-pneumonia
An effectiveness of zero (0) for PPSV23 against all-cause
pneumonia was assumed; based on several studies that
also have served as information source in other economic
Figure 1 Markov microsimulation model of pneumococcal diseases to determine the cost-effectiveness of vaccination with PCV13,
PPSV23 or not vaccine, in people older than 50 years in Colombia.
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assessments [40-45]. For PCV13, effectiveness observed
in children with radiological-confirmed pneumonia was
assumed in inpatient pneumonia and it was adjusted
for the effect of immune-senescence following a similar
procedure as described with IPD [10]. For outpatient
pneumonia, the starting point for effectiveness estimation
was 6%, based on the percent reduction in children with
pneumonia without radiological confirmation [11]. We as-
sumed the same decline rate of effectiveness adjusted by
age, used in patients over 50 years with IPD. In immuno-
compromised patients, it was assumed a PCV13 effective-
ness of 65% less than immunocompetent adults of the
same age, based on data of Klugman et al. [37] (Table 3).
Economic parameters
Vaccine costs were taken from the Pan American Health
Organization Revolving Fund prices; which lists values
of different vaccines for the Americas in 2013; cost per
dose of PCV13 is U.S. $ 15.84 and cost per dose of
PPSV23 is U.S. $ 6.60 [46]. For administration cost for
application of either vaccine, we assumed a value of U.S.
$ 1. To calculate these values in American dollars, we as-
sumed a value of $COP 1800 per U.S. $ 1 [47].
To determine the costs of treatment of sepsis, men-
ingitis and pneumonia in adults over 50 years in Colombia,
we took the information from a health insurance com-
pany with national presence and over 1.8 million mem-
bers, which ensures the representativeness of Colombian
population. Costs were determined based on the value
actually paid by insurance companies to different hospi-
tals and includes all services rendered during the stay
including visits-hospital, diagnostic aids, antibiotics and
other treatments necessary for recovery until discharge.
Table 1 Demographic and epidemiological parameters on
the likelihood of developing pneumococcal diseases in
people over 50 years in Colombia, 2012
Parameter Mean value Data distribution Reference
Population distribution No variation [31]
50 – 64 years 5′963,690
65 – 74 years 1′987,534
75 – 79 years 641,029
80 – 99 years 630,983
Discount rate 3% No variation Assumption
Vaccination coverage 70% Beta Assumption
Epidemiological parameters:
Incidence of bacteremia: Beta [24]
50-64 years 0.0667%
≥ 65 years 0.181%
Incidence of meningitis: Beta [24,25]
50-64 years 0.0046%
≥ 65 years 0.0114%
Incidence of all-cause pneumonia: Beta [24,25]
50-64 years 0.3281%
≥ 65 years 2.1627%
Bacteremia mortality: Beta [23,31]
50 – 64 years 3.5%
65 – 74 years 5.7%
75 – 84 years 11.4%
85 – 99 years 27.5%
Meningitis mortality: Beta [23,31]
50 – 64 years 26.7%
65 – 74 years 19.5%
75 – 84 years 37.4%
85 – 99 years 40.0%
Inpatient pneumonia mortality: Beta [23,31]
50 – 64 years 0.9%
65 – 74 years 2.9%
75 – 84 years 6.2%
85 – 99 years 14.6%
Costs (U.S. $)
Inpatient pneumonia Mean (SD)
50 – 64 years 1,765 (4,005) Gamma Sura EPS
(local data)65 – 74 years 1,932 (4,721)
75 – 79 years 2,688 (12,332)
80 – 99 years 1,309 (3,355)
Bacteremia
50 – 64 years 10,434 (16,835) Gamma Sura EPS
(local data)65 – 74 years 8,495 (10,782)
75 – 79 years 6,753 (10,380)
80 – 99 years 4,849 (9,772)
Table 1 Demographic and epidemiological parameters on
the likelihood of developing pneumococcal diseases in
people over 50 years in Colombia, 2012 (Continued)
Meningitis
50 – 64 years 7,789 (8,114) Gamma Sura EPS
(local data)65 – 74 years 7,783 (8,025)
75 – 79 years 7,783 (8,025)
80 – 99 years 7,783 (8,025)
Table 2 Distribution of people in each age group, with
low, medium or high risk for pneumococcal diseases or
their complications [21]
Age groups Risk level
Low Medium High
50 – 64 years 52.2% 36.6% 11.2%
65 – 74 years 41.7% 38.5% 19.8%
75 – 84 years 37.4% 36.9% 25.7%
85 – 99 years 36.6% 34.3% 29.1%
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These costs are based on national tariff manuals. In 2012,
this insurance company reported a total of 48 cases of
meningitis, 1 526 cases of pneumonia and 389 cases of
sepsis. These costs were validated with data from a
study in three hospitals in Bogota, Colombia, for a
period of 18 months in 2011 [48]. The values were
adjusted at 3.73%, which was the Consumer Price Index
for 2011 reported by National Administrative Department
of Statistics of Colombia (DANE by their acronym in
Spanish) [23].
Sensitivity analysis
Probabilistic and univariate sensitivity analyses were made
for epidemiological parameters, effectiveness of interven-
tions, and costs included in the model. The parameters
that generated a higher level of uncertainty were identified
and variance reported. For probabilistic sensitivity analysis
a Monte Carlo simulation with a thousand iterations was
performed, in order to evaluate each expected value in the
distribution of costs and diseases likelihood for each
strategy. In the base case, the probabilistic sensitivity ana-
lysis report both there were 7,5000,000 simulations and
1,000 trials.
We assumed a gamma distribution for medical costs
avoided and the costs of vaccines, considering the kurtosis
thereof. Alpha and beta parameters were calculated from
standard deviations of the actual data. Results of Monte
Carlo simulation show robustness of the model. A univari-
ate sensitivity analysis was made with minimum and
maximum values, with the aim to observe the sensitivity
of ICER to change in the parameters of each variable.
Cost-effectiveness analysis
A cost-effectiveness analysis was made to calculate the
ICER of vaccines and number of avoided cases in rela-
tion to the four conditions of interest: sepsis, meningi-
tis, inpatient pneumonia, and outpatient pneumonia.
The calculation was made considering in numerator the
costs difference of both alternatives and in denominator
their effectiveness difference. Costs were result of the value
of one dose of PCV13 or PPSV23, as well as the lower cost
incurred on medical treatment for least number of cases
of each disease.
Cost-effectiveness analysis of vaccines in relation to
specific mortality from sepsis, meningitis and pneumo-
nia and mortality added were made also. Finally, a cost-
effectiveness analysis was made in relation to the LYG
for each strategy.
Results
Compared to no vaccination, use of PCV13 in adults over
50 is expected to prevent 49 857 cases of pneumococcal
bacteremia; 3 135 of pneumococcal meningitis; 496 795 of
inpatient pneumonia, 866 189 of outpatient pneumonia;
and 33 980 deaths from pneumococcal infections, over
5 years. Moreover, total costs with the not vaccinating
strategy were U.S. $ 145,196,578 greater than vaccinating
with PCV13 (Table 4).
Both vaccination strategies would prevent more deaths
and IPD that no vaccination and PCV13 would reduce
more than PPSV23. A mass vaccination program in
Colombia for adults over 50 years with PCV13 would
avoid 79 633 additional cases of pneumonia, both in-
patient and outpatient, to those prevented with PPSV23.
Furthermore, PCV13 would prevent and additional 5 127
cases of IPD and 3560 deaths by pneumococcal infections,
more than PPSV23 (Table 4).
Total costs (medical costs and vaccination) were highest
with the strategy of not vaccinating, and both PPSV23 and
PCV13 were cost saving compared with no vaccination.
However, vaccination with PCV13 saves U.S. $ 97 million
versus PPSV23 (Table 4).
Cost-effectiveness analysis
PCV13 is dominant over PPSV23 in terms of mortality
avoided and LYG in adults over 50 years, because PCV13
avoids more deaths, generates more LYG, and healthcare
costs expected would be lower than PPSV23. ICER indi-
cates that PCV13 would be dominant over PPSV23, both
in terms of illness and deaths averted by pneumococcal
disease as well as LYG (Table 4).
Sensitivity analysis
PCV13 would prevent 52.0% of the cases of pneumo-
coccal bacteremia and meningitis and 12.6% of all-causes
Table 3 PCV13 and PPSV23 effectiveness to prevent IPD in inpatient and outpatient pneumonia in adults over 50
















50 – 64 88.9% 24.2% 5.6% 79.2% 0.0% 0.0%
65 – 74 81.5% 21.9% 5.1% 61.6% 0.0% 0.0%
75 – 79 75.7% 20.2% 4.7% 50.4% 0.0% 0.0%
80 – 99 70.3% 18.7% 4.3% 42.1% 0.0% 0.0%
IPD: Invasive Pneumococcal Disease.
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pneumonia versus no vaccination strategy, unlike PPSV23
that would prevent 26.9% and 6.2%, respectively (Table 4).
In the probabilistic sensitivity analysis, among one
thousand simulations of the model, PCV13 had a lower
cost than PPSV23 in 100% of cases, there was more
LYG in 64% of cases and it was cost-effective in 87% of
cases, taking into account a willingness to pay of 3 GPD
(U.S. $ 23,799) [49] (Figure 2).
In the same way, in cost effectiveness plane, PCV13 is
dominant over PPSV23 and no vaccination, which is due
to be a strategy with greater clinical effectiveness and
lower costs (Figure 3).
Discussion
This cost-effectiveness analysis has identified both clinical
and economic outcomes of the alternatives that exist in
the Colombian market to prevent pneumococcal diseases
in adults over 50 years: PCV13 and PPSV23. From the
perspective of a third-party payer, both strategies are
dominant versus non-vaccination, in terms of avoided
diseases and deaths, ICER, and LYG. In addition, PCV13
was cost-saving, and is below the threshold of 1 per capita
gross domestic product Colombian in 2012 (estimated
at U.S. $ 7.933) [49], according to WHO recommenda-
tions [50].
Since 2009, several Colombian cities are including
PPSV23 within their immunization plan. In 2011, PCV13
received health registration for use in people over 50 years
to prevent pneumococcal diseases. Results of this cost-
effectiveness analysis are intended to generate information
to make decisions regarding the choice of two options that
are on the market.
The results of this cost-effectiveness analysis are similar
to those reported recently by Smith et al. and Weycker
Table 4 Cases and direct costs by pneumococcal infections vaccinating with PCV13, PPSV23, or not vaccine in people
over 50 years in Colombia
Parameters PCV13 PPSV23 No vaccination (NV) PCV13-PPSV23 PCV13-NV
Number of cases
Bacteremia 34 934 39 809 49 857 −4 875 (−12.2%) −14 923 (−29.9%)
Meningitis 2 306 2 557 3 135 −252 (−9.8%) −830 (−26.5%)
Inpatient pneumonia 439 971 496 752 496 795 −56 781 (−11.4%) −56 824 (−11.4%)
Outpatient pneumonia 841 546 864 397 866 189 −22 852 (−2.6%) −24 644 (−2.8%)
Deaths by pneumococcal infections 29 726 33 285 33 980 −3 560 (−10.7%) −4 255 (−12.5%)
LYG 11 377 2 290 0 9 087 11 377
Total costs (million)
Medical costs U.S. $ 1,286.2 U.S. $ 1,439.7 U.S. $ 1,534.9
Vaccine costs U.S. $ 103.6 U.S. $ 47.6 –
Total U.S. $ 1,389.8 U.S. $ 1,487.3 U.S. $ 1,534.9 U.S. $ -97.5 U.S. $ -145.1
Figure 2 Probabilistic sensitivity analysis, which plotted life years gained versus costs for PCV13 and PPSV23 in a cohort of people
over 50 years in Colombia, 2012.
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et al. in the US, both of which concluded that PCV13 in
adults over 50 years of age is a better strategy than PPSV23
in terms of cost-effectiveness, to prevent pneumococcal
infections in adults in the United States [24,51].
Although this cost-effectiveness analysis only considered
the use of one dose of both, PCV13 or PPSV23 because
the time horizon was five years, it is important to note that
if the time horizon would have been the life expectancy,
two doses of PPSV23 should be used for people at high
risk, according to its manufacturers.
In the other hand, a meta-analysis published by
Moberley et al. recommends PPSV23 versus placebo to
prevent pneumococcal diseases [52]. RCTs used in that
meta-analysis and published between 1980 and 2006 did
not found any evidence about PPSV23 as protective vac-
cine to avoid pneumonia [40,41,53-58]. It means that the
conclusion of Moberley et al. is based on only two RCTs:
Kaufman (1948) [13] and Riley (1977) [59]. It is important
to note that these RCTs [13,59] did not identified infection
by S. pneumoniae but Diplococcus pneumoniae, which is a
different microorganism.
Clinical effectiveness of pneumococcal conjugate vac-
cines for IPD in adults is judged by non-inferiority of
antibody response compared with PPSV23. Jackson et al.
showed that in people aged 70 years and older, opsono-
phagocytic activity titers were significantly greater in the
PCV13 group versus PPSV23 group for 10 of the 12
serotypes common to both vaccines and to serotype 6A
which is only in PCV13. Responses were non-inferior
for the other 2 common serotypes [60]. Much effectiveness,
particularly in pneumonia, is inferred based on PCV13 be-
ing a conjugated vaccine and eliciting a T-cell dependent
response. This is supported by effectiveness in children
reducing pneumonia and nasopharyngeal carriage, in fact,
Cappuy et al. demonstrated that 2 to 4 years following
PCV7 introduction, predominant pneumococcus serotypes
carried in children with community-acquired pneumonia
were non PCV7 serotypes [61].
A main strength of this study is that it has local informa-
tion, which helps determine the epidemiological parameters
for diseases of interest in Colombia [31]. Also, medical
costs of treatments are based on local data [46] and are
not supposed on studies done in other countries with
different economic realities. In the same way, to adjust
efficacy of both vaccines based on pneumococcal sero-
types circulating in the country between 2005 and 2010,
allows having an updated analysis [21]. So, by having local
and updated economic and epidemiological information,
we can develop a robust economic model, that allows
to national and regional health authorities assess their
vaccination plans and take decisions.
The biggest limitation of this study is that there is not
effectiveness data for PCV13 in this population. However,
the advantages of conjugation are expected to enhance ef-
fectiveness against mucosal disease, such as pneumonia,
increase immune memory compared to plain polysacchar-
ide vaccine, and improve effectiveness in high risk popula-
tions such as immunocompromised. In a study of PCV7
versus placebo in HIV patients, French et al. found a
vaccine efficacy of 74% (95% CI: 30% - 90%) to prevent
pneumococcal diseases [18]. In other study, Klugman
et al. found that vaccination with PCV9 reduced the
rates of radiologically confirmed pneumonia, and PCV9
also reduced the incidence of vaccine-serotype and
antibiotic-resistant IPD among children with and those
without HIV infection [37].
Another weakness of this study, is that there is limited
information comparing clinical outcomes of PPSV23 and
PCV13 in adults to prevent IPD, which are the most lethal
diseases caused by pneumococcus. In the same way, by
taking data of disease prevalence from an official source,



















Figure 3 Number of cases avoided with PCV13 and PPSV23 compared to no vaccination in a cohort of people over 50 years in
Colombia, 2012.
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kind of information depends that medical practitioners
use the correct codes to identify diagnosis.
This analysis did not evaluate after-effects of any of
the diseases, why not were estimated years of disability-
adjusted life. But it is noteworthy that in terms of preven-
tion of death from all causes, PCV13 was dominant over
PPSV23.
Conclusion
The results of this study indicate that PCV13 and PPSV23
are better alternatives in terms of cost-effectiveness
compared with no vaccination. PCV13 is dominant over
PPSV23, since PCV13 prevents more deaths by pneumo-
coccal diseases, generates more LYG, and costs are ex-
pected to be lower than PPSV23 in adults over 50 years.
Implementation of a vaccination program for adults older
than 50 years in Colombia with PCV13 would decrease
morbidity and mortality by pneumococcal diseases and
would be a cost-saving strategy.
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